癌症药物提振业绩,强生Q1业绩超预期,上调全年营收预期 | 财报见闻

华尔街见闻
15 Apr

得益于其癌症治疗药物,包括多发性骨髓瘤药物Darzalex的强劲销售表现,强生公司营收和利润均超出华尔街预期。美东时间周二美股盘前,强生公布了一份超出预期的财报:EPS:Q1调整后每股收益同比增长2.2%至2.77美元,高于市场预期的2.60美元;营收:Q1营收同比增长2.4%至219亿美元,高于预期的215.8亿美元;股息:强生将季度股息提高4.8%,从1.24美元每股上调至1.30美元每股;...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10